LEXX - Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension Epilepsy Treatments
- The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11%
- Drug developers are shifting focus to the development of lipophilic drug compounds, which increases bioavailability
- DehydraTECH-enabled drugs improve the speed of onset, increase bioavailability, increases brain absorption, and reduces drug administration costs
- Lexaria’s DehydraTECH has 34 patents granted worldwide and many more pending across several categories of fat-soluble active molecules and drugs
- The company operates through four separate subsidiaries to explore the potential and options for the use of DehydraTECH in respective industries
Bioavailability is the ability of a drug or other substance to be absorbed and used by the body – and in recent years, it has become an integral part of drug pharmacokinetics. The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11%. Drug developers have shifted focus to developing lipophilic drug compounds, undertaking new efforts to identify enhancement techniques that mitigate the challenge of low bioavailability and stability (https://cnw.fm/6uTZv).
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed its patented DehydraTECH(TM) technology to improve how active pharmaceutical ingredients (“APIs”) enter the...
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at http://cnw.fm/LEXX
About HempWire
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text "HempWire" to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.HempWire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer
Do you have questions or are you interested in working with HW? Ask our Editor
HempWire (HW)
Denver, Colorado
www.HempWire.com
303.498.7722 Office
Editor@HempWire.net
HempWire is part of the InvestorBrandNetwork.